The treatment against metastatic ESCC is still challenging, and immunotherapy with anti‐PD‐1 mAb is becoming a promising novel strategy,3, 34, 35, 36, 37 in which inhibition of PD‐L1 and PD‐1 interaction with the anti‐PD‐1 mAb resulted in the significant clinical response in the early phase clinical trial for advanced ESCC. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.